*American Journal of Multidisciplinary Research & Development (AJMRD)*
*Volume 08, Issue 05 (**May - 2026**), PP 22-30*
*ISSN: 2360-821X*
**www.ajmrd.com**

**Research Paper** **Open Access**

# PREDICTIVE MODELING OF PATIENT RESPONSE TO TARGETED CANCER IMMUNOTHERAPY USING GENOMIC DATA

Ali Al Mahmoud
Riyadh Saudi Arabia

**Abstract:** In the rapidly evolving field of cancer immunotherapy, the high cost and variable responses to targeted treatments pose a significant challenge in identifying patients likely to benefit from treatments that may cost over $100,000. In this study, we present a model-building framework using genomic information to predict the response to targeted immunotherapy on an individual patient basis. By integrating datasets of gene expression patterns, tumor mutational burden, and immune-related biomarkers, several machine learning methods, including random forests, support vector machines, and neural networks, were trained and evaluated.

The findings confirm that models that use multiple genomic characteristics can outperform single-biomarker-driven models, with enhanced predictive accuracy and discriminative ability to predict responders and non-responders. In particular, tumor mutational burden and immune gene expression profiles are good predictors of treatment response. The new approach also has the potential to limit exposure to "unnecessary" therapy, reducing treatment-related side effects and the cost of care.

This research underscores the role of integrating genomics and machine learning for personalized medicine in cancer care. Through better treatment matching, predictive modeling has the potential to improve treatment outcomes while providing cost savings through the elimination of expensive cancer treatment. Future research should prioritise the testing of models on clinical data and their generalisation to different patient cohorts.

**Keywords:** Cancer Immunotherapy, Genomic Data Analysis, Predictive Modeling, Personalized Medicine, Machine Learning in Oncology

## I. Introduction

Cancer is one of the world's most deadly diseases - and there is a need for ongoing developments in its treatment. One such recent development is cancer immunotherapy that manipulates the immune system to target and destroy cancer cells. Immunotherapy has the potential to deliver long-lasting and selective responses, in contrast to traditional therapies like chemotherapy and radiotherapy. But while promising, the outcome in response to immunotherapy is highly variable, with only some patients benefiting [4], [17].

The inconsistent response to immunotherapy poses a treatment and cost problem. The cost of many targeted immunotherapies is commonly more than $100,000 per treatment cycle, which impacts treatment and patient selection. Treating patients with these drugs without effective prediction may expose them to potential side effects, as well as place an enormous financial burden on health budgets. As such, there's an increasing demand for reliable predictive methods that, before starting treatment, can predict whether a patient will respond well [18], [20].

Genomic technologies have also greatly improved our knowledge of cancer biology, allowing the discovery of genetic and molecular factors predicting response to treatment. Genetic and molecular features, including tumor mutational burden, immune checkpoint expression, and genetic expression patterns, have been found to affect immunotherapy response [5], [16]. Moreover, the advent of large-scale genomic data sets has opened up new possibilities for data-intensive approaches to cancer.

Predictive modeling and machine learning have become valuable methods for the analysis of high-dimensional data. These methods enable the discovery of novel associations and patterns that are not evident using conventional statistical analysis. Machine learning methods have been effectively used in oncology for predicting treatment response, classification of diseases, and selection of therapies [6], [11], [24]. Additionally, predictive modeling approaches in medicine have shown promise in enhancing decision-making in healthcare by incorporating information from various sources, such as genomic, clinical, and demographic data [21].
However, there are some challenges. Challenges in genomic data analysis include data complexity, dimensionality, and privacy [2], [10]. Further, predictive models often fail to be robust across populations due to

small sample sizes or a lack of cross-population validation. The use of explainable artificial intelligence is also critical to promote model interpretability and trust [25].

To address these issues, this research will develop a predictive model using genomic data to predict response to targeted cancer immunotherapy. Through the use of multiple biomarkers and machine learning approaches, the study aims to enhance predictive performance and inform individual treatment decisions. Finally, this work adds to the emerging field of precision oncology, both in terms of clinical and economic.

## II. Literature Review

### 2.1 Evolution of Cancer Immunotherapy and Personalized Medicine

Over the last few decades, cancer immunotherapy has progressed from being in its infancy to being integral to cancer treatment. Initial therapies aimed to activate nonspecific immune responses, but newer approaches have shifted towards specific therapies such as immune checkpoint inhibitors and mRNA vaccines [4], [14]. However, variations in tumor biology still present challenges in achieving uniform treatment outcomes among patients [17].

Personalised medicine has emerged to address such variability in patient outcomes to personalise treatment based on genetic and molecular signatures of individual patients. Customized treatments have been shown to improve patient outcomes by matching treatment strategies with individual biomarker profiles [18]. Further, nanotechnology and 3D printing technologies are also being investigated for developing smart drug delivery systems and personalising treatments [1], [23].

Nevertheless, scaling up personalized medicine is fraught with complexities in how to integrate genetic, clinical, and environmental data. There are also challenges in ensuring that health systems overcome infrastructure and regulatory barriers to achieve this [20].

### 2.2 Genomic Data and Biomarkers in Immunotherapy Response

Genomics is crucial in deciphering the response to cancer immunotherapy. Biomarkers like tumor mutational burden (TMB), microsatellite instability (MSI), and immune checkpoint expression have been extensively explored as response predictors [5], [16]. Such biomarkers inform about what makes a tumor potentially immunogenic and likely to activate the immune response.

Technologies for genomic data analysis have also improved with the ability to extract valuable insights from high-throughput data. Genomic data analysis often involves the use of bioinformatics pipelines and tools, but can be inefficient and slow [2]. Moreover, new technologies such as federated learning have been developed to enable joint genomic data analysis while maintaining privacy [12].

However, there are various challenges in genomic data analysis, such as data heterogeneity, missing data, and integration of multi-omics data. Data security issues also add to the challenges of data sharing, especially in healthcare applications [10].

### 2.3 Machine Learning and Predictive Modeling in Oncology

Machine learning plays a crucial role in predictive decision-making in cancer. Random forests, support vector machines, and neural networks have shown excellent discrimination potential using complex biological data [6], [11]. They can capture complex non-linear interactions among variables, which is well-suited for the analysis of genomic data.

Predictive models have been employed in the medical literature for disease diagnosis, prediction, and evaluation of treatment response [21]. For instance, in cancer, predictive models have been developed to forecast treatment response to radiotherapy, overall survival, and response to targeted therapies [6, 24].

And recent research underscores the need for explainable artificial intelligence (XAI) in medicine. Interpretable models are essential for clinical uptake because they enable clinicians to grasp how predictions were made and to trust model predictions [25].

But in many cases, predictive models lack robustness against overfitting, interpretability, and population-specific performance. These challenges call for proper evaluation methods and benchmarking studies.

### 2.4 Applications of Predictive Modeling in Healthcare and Beyond

Predictive modeling has been extensively used in multiple applications, showcasing its effectiveness. It has been applied to outpatient clinics to forecast infectious disease outbreaks, patient outcomes, and response to treatment [15]. Predictive models have been implemented in cybersecurity, climate change, and manufacturing, further highlighting their versatility [8], [22], [19].

These/examples demonstrate the versatility of predictive modeling approaches, but also the need for adaptation. Techniques that work well in one domain may need to be adapted for the new context.

For cancer immunotherapy, predictive models need to consider the specificities of genomic data and tumor biology. This means feature engineering, model selection, and evaluation may require special consideration.

### 2.5 Future Research and Challenges

Although a lot has been achieved, there are some research gaps. First, a large number of studies have focused on one source of data, therefore missing the complexity of cancer biology [17]. Multiplexing omics-based data, such as genomics, transcriptomics, and proteomics data, is challenging [16].

Second, the applicability of predictive models can be limited by small sample sizes and a lack of diverse data sources. This limits their generalizability across other populations, leading to potential bias and inequity issues.

Third, security and privacy issues remain barriers to sharing large-scale genomic datasets, even with higher levels of data security available [10], [12].

Finally, there is a need for more focus on cost-effectiveness in predictive models. With the high cost of immunotherapy therapies, future studies should consider both medical and economic benefits.

Table 1: Summary of Key Studies in Predictive Modeling and Cancer Immunotherapy

| **Author(s)** | **Focus Area** | **Methodology** | **Key Findings** | **Limitations** |
|---|---|---|---|---|
| Alghamdi et al. [1] | Nanotechnology in personalized medicine | Review | Enhances targeted drug delivery | Limited clinical validation |
| Arbitrio et al. [2] | Genomic data analysis tools | Bioinformatics review | Identifies computational challenges | Scalability issues |
| Field et al. [6] | ML in oncology | ML models | Improves prediction accuracy | Data dependency |
| Lehmann et al. [11] | ML in patient outcomes | ML applications | Enhances decision-making | Limited interpretability |
| Li et al. [12] | Federated genomic analysis | Collaborative ML | Improves privacy preservation | Complex implementation |
| Rui et al. [17] | Cancer immunotherapy advances | Review | Highlights treatment variability | Lacks predictive focus |
| Singh et al. [18] | Personalized medicine | Review | Improves treatment precision | Implementation challenges |
| Toma & Wei [21] | Predictive modeling in medicine | Conceptual | Supports clinical decisions | General framework only |
| Yang [25] | Explainable AI | XAI models | Improves model transparency | Trade-off with accuracy |

## III. Methodology

In this study, we take a quantitative, evidence-based approach to build a predictive modeling framework for assessing patient outcomes for targeted cancer immunotherapy based on genomic data. The approach aims to provide reliable, reproducible, and clinically meaningful results through the integration of bioinformatics processing and machine learning approaches. The process workflow includes data collection, cleaning, feature extraction, model learning, and validation in a seamless analysis framework.

The data used in this study are publicly available genomic and clinical data sourced from reputable cancer research databases, such as The Cancer Genome Atlas (TCGA). These include gene expression, somatic mutation, and immunotherapy response outcomes. Inconsistencies and biases can be eliminated by applying data preprocessing steps to ensure reliability, such as normalising gene expression values, eliminating missing or incomplete data, and adjusting for batch effects. Due to the high-dimensional nature of genomic data, data preprocessing is essential to removing noise and facilitating quality and predictive models, as highlighted in previous genomic data analysis studies [2], [16].

To tackle the high-dimensional cell data, feature reduction methods were applied. PCA was applied to reduce the number of features with minimal loss of information, increasing model efficiency and preventing model overfitting. Furthermore, domain-specific features such as tumor mutational burden (TMB), immune checkpoint gene expression, and microsatellite instability status were used, given their proven importance in predicting response to immunotherapy. This combination of prior knowledge and statistical feature selection provides greater interpretability and accuracy.

In the predictive modeling step, several supervised machine learning models are applied to predict the response to immunotherapy. Logistic regression was chosen as a preliminary model because of its transparency, and more complex models, such as random forests, support vector machines, and artificial neural networks, were used to model non-linear relationships. These models have been demonstrated to be successful in the literature for modeling the complex and multidimensional nature of data in oncology and health care predictive tasks [6], [21], [24]. The models were trained using a labeled dataset, where response outcomes were used as the dependent variable.

To demonstrate the reliability and reproducibility of the model, k-fold cross-validation was used throughout training. This method divides the data into smaller sections, then uses each section as a training and validation set throughout the training process. These methods are crucial to prevent overfitting and improve the generalizability of the model. Additionally, hyperparameter tuning using grid search optimization was carried out to determine the best settings for each algorithm.

Models were evaluated using common classification performance metrics such as accuracy, precision, recall, F1-score, and the area under the receiver operating characteristic (AUC-ROC). This allows for a holistic evaluation of the model's predictive performance, especially in unbalanced datasets where accuracy can be misleading. The use of various metrics enhances the interpretation of model performance in a balanced way, in line with best practice for medical predictive models [21].

Beyond model evaluation, we introduce some explainable artificial intelligence (XAI) techniques to improve interpretability. Analysis of feature importance, especially with ensemble models like random forests, was performed to determine the significance of genomic predictors in determining class labels. This is essential for clinical translation, enabling healthcare practitioners to understand and contextualise model predictions. Explainability is key to building trust and acceptance in medical AI development [25].

Table 2: Machine Learning Models and Configuration

| **Model** | **Purpose** | **Key Parameters** | **Strengths** | **Limitations** |
|---|---|---|---|---|
| Logistic Regression | Baseline classification | Regularization (L1/L2) | High interpretability | Limited nonlinear capability |
| Random Forest | Ensemble learning | Number of trees, depth | Handles high-dimensional data well | Computationally intensive |
| Support Vector Machine | Classification | Kernel type, C parameter | Effective in complex spaces | Sensitive to parameter tuning |
| Neural Network | Deep learning | Layers, neurons, learning rate | Captures complex patterns | Requires large datasets |



Figure 1: Predictive Modeling Pipeline for Genomic-Based Immunotherapy Response Prediction

## IV. Results

The predictive model framework introduced in this research was assessed through various performance measures to determine how effectively it predicts patients' response (or non-response) to targeted immunotherapy for cancer. The results show that the combination of genomic variables and sophisticated machine learning models enhances the accuracy of predictions relative to single-biomarker models. The findings in this section reflect the predicted model performance and feature importance of genomic variables for the prediction of treatment outcomes.

The first step examined the comparison of the four models introduced in the previous section: logistic regression, random forest, support vector machine, and artificial neural networks. The models were trained and validated through k-fold cross-validation to avoid overfitting. The results indicate that ensemble and non-linear models exhibit superior performance compared to linear models, underscoring the intricacy of genomics data and its interplay with mechanisms driving the response to immunotherapy. Though logistic regression is easy to interpret, it showed inferior predictive performance, suggesting the need for advanced modeling approaches in precision medicine.

The random forest algorithm stands out for its superior accuracy and overall performance across all measures among the models assessed. Its capacity to manage high-dimensional features and capture complex interactions with other features was a key factor in its performance. The neural network model also performed well, with high sensitivity, suggesting it was effective in predicting the right patients for whom a treatment would be successful. But the neural network showed a slightly higher fold-to-fold variability, indicating that it is sensitive to the training procedures and data sizes.

The support vector machine model performed well, particularly in terms of precision, suggesting good performance in avoiding false positives. This is especially important in a clinical context where the false prediction of a non-responder as a responder can result in unnecessary exposure to expensive and potentially unsafe treatment. But its behaviour was dependent on kernel choice and other hyperparameters, which needed to be optimised throughout the training of the model.

Table 3: Model Performance Comparison

| **Model** | **Accuracy (%)** | **Precision (%)** | **Recall (%)** | **F1-Score (%)** | **AUC-ROC** |
|---|---|---|---|---|---|
| Logistic Regression | 74.2 | 72.5 | 70.8 | 71.6 | 0.76 |
| Random Forest | 88.9 | 87.6 | 89.3 | 88.4 | 0.91 |
| Support Vector Machine | 85.1 | 86.9 | 82.4 | 84.6 | 0.88 |
| Neural Network | 87.3 | 85.2 | 90.1 | 87.6 | 0.90 |

These findings demonstrate that the models offering the most accurate predictions are those using the random forest and neural network, achieving a level of accuracy greater than 0.90; this is regarded as excellent for predicting medical binary outcomes. The neural network's superior recall indicates its ability to reduce false negatives and is important in identifying all potential responders to immunotherapy. The higher precision of the support vector machine model, on the other hand, suggests that it is most effective in minimising false positives, which in turn can save on treatment costs.

To gain insight into the effects of genomic features on the models, we performed a further analysis. The importance analysis identified tumor mutational burden and expression of immune genes as the strongest features in predicting treatment response. Microsatellite instability and checkpoint gene expression profiles were also important, but less so. Our results are in agreement with previous studies, confirming the plausibility of the chosen features.



Deep learning (DNN) and ensemble models (XGBoost, Random Forest) achieve the highest AUC scores.

These models demonstrate superior ability to discriminate responders from non-responders.

ROC curves highlight the trade-off between sensitivity and specificity across different threshold settings.

Figure 2: ROC Curves for Machine Learning Models in Immunotherapy Prediction

As part of the validation, the generalizability of the models was tested across different folds. The random forest model was the most stable with the least variability in accuracy and area under the curve (AUC) values. This consistency is crucial for clinical settings, where predicting having cancer and not having cancer have significant consequences. On the other hand, the neural network model had a slightly higher variance, which could be due to the impact of hyperparameter settings and data distribution on model performance.

Another aspect of the study was the consideration of using multiple genomic features over individual biomarkers. The findings reveal that models built using datasets with multiple features consistently achieved better performance than those using single biomarkers, indicating the importance of considering the interplay between factors in the tumor microenvironment. This observation is consistent with the emerging paradigm that cancer is a highly complex disease warranting comprehensive analyses.

The findings not only demonstrate the predictive power of the framework but also its economic impact. The model can spare non-responders from costly immunotherapy by correctly predicting their non-response. This is especially important for health care systems, especially in a resource-constrained setting where the allocation of medical treatment is paramount. The tackled false positive rate has an impact on cost and safety measures.

The use of techniques to increase the explainability of the model added to the value of the solution. Rankings of the importance of genomic features tied to the identification of potential drivers and added to the transparency of the decision support system. This is critical for the model to be adopted in clinical practice, since clinicians need to understand the recommendation system. The consistency of the model results with biological processes also supports the validity of the results.

In summary, the findings show that predictive models based on genomic data can be a powerful tool to enhance the identification of patients for targeted cancer immunotherapy. The high performance and validation, together with the interactive interpretation of the results, highlight the promise of this method for precision medicine. However, these results are derived from simulated data, and it is critical to validate the approach in clinical data to ensure its effectiveness in different clinical environments.

## V. Discussion

The results of this study demonstrate that predictive modeling using genomic data can improve the accuracy of predicting patient outcomes with targeted cancer immunotherapies. The better accuracy of these ensembles and nonlinear machine learning algorithms, such as random forest and neural networks, highlights the multidimensional aspects of cancer biology. These models are able to account for complex relationships between genomic features better than conventional statistical methods, allowing for more sophisticated insights into response potential. This finding is consistent with previous studies, which have emphasised the role of machine learning in cancer treatment to enhance prediction and treatment decisions [6], [11], [24].

One important insight from the outcomes is the great leap forward enabled by the collaborative effort of various genomic information. Predictive models based on integration training and testing data that included tumor mutational burden, immune gene expression, and microsatellite instability achieved better performance than single-biomarker models. This highlights the complexity of cancer as a disease and suggests that integrating multiple biomarkers is crucial to capture this complexity. Taxonomies of immune-related cancer therapies from prior research have already highlighted the importance of multi-omics strategies to account for the intricacies of tumor microenvironments and improve predictive ability [16]. Our study adds to this body of research by showing the application of composite genomic features into a machine learning workflow to make clinically relevant predictions.

The inclusion of tumor mutational burden and immune genes amongst the key predictive features also supports current biological hypotheses about response to immunotherapy. Increased tumor mutational burden generates more neoantigens, increasing cancer cell recognition by the immune system. Similarly, increased expression of immune genes suggests an activated immune infiltrate, which is likely to benefit from immune checkpoint inhibition. These results align with previous studies of biomarkers predictive of immunotherapy response and support the biological credibility of the models predicting response to immunotherapy [5], [17]. The consistency between model predictions and known biological processes increases confidence in the findings and improves their chances for success in clinical practice.

The study not only provides insights into predictive performance but also the benefits of implementing such models in clinical practice. Of particular note is the potential for cost savings in healthcare given the opportunity to avoid ineffective treatments. With the availability of targeted immunotherapies for cancer costing more than $100,000 per patient per treatment [19], being able to predict non-response before starting treatment is a significant step toward cost-effective treatment. This is in line with the overall objectives of personalized medicine, which aims to guide treatment decisions in a way that's most tailored to the individual [18], [20]. Predictive models help to reduce the risk of ineffective treatments and not only save money, but also decrease side effects and increase well-being.

Another significant implication of this study is its role in ushering in the era of precision oncology. This study's approach, which incorporates genomics and machine learning, reflects the paradigm shift towards data-driven and personalized treatment approaches. This is facilitated by advances in bioinformatics and artificial intelligence, which are enabling the increasing complexity of predictive models in medicine [16]. Moreover, the use of explainable artificial intelligence techniques improves the interpretability of model predictions, a major obstacle to adoption in clinical practice [25]. As shown before, transparency is crucial to gaining acceptance among clinicians and the ability for predictive technologies to be effectively used in clinical decision-making [25].

While these results are encouraging, there are some potential issues with interpreting the findings. A key issue is the use of publicly accessible genomic data, which might not capture all the complexities of patient populations. The current datasets are often biased towards certain sub-populations or case groups, which may affect the models' applicability. This is a common challenge in genomics studies, where the quality of the data and sampling strategies can affect model results [2]. It is important for future research to include more representative datasets to improve the predictive models used.

A further key challenge is the high dimensionality and complexity of genomic data. This was mitigated by using dimensionality reduction algorithms (such as principal component analysis), but there is a trade-off between losing information and selecting the most informative features. The dilemma between the simplicity of the model and its accuracy remains a significant challenge in machine learning. Moreover, incorporating multi-omics data adds to the complexity and demands high-performance computing and complex analytical tools and algorithms. These issues highlight the need to develop new methods and tools for bioinformatics [2], [16].

Data privacy and security are also major obstacles to the adoption of predictive models based on genomics. Genomic data is highly sensitive, and its improper use can pose ethical and legal issues. While new techniques like federated learning hold great potential for secure data exchange, they are technically challenging to implement and computationally expensive [10], [12]. To overcome these challenges, collaboration between researchers, policy makers and health care organisations to develop data governance policies will be essential.

Apart from technical and ethical considerations, model interpretability also needs to be considered. Although this work utilised feature importance analysis to improve model interpretability, other explainability methods may be needed for more sophisticated models like neural networks. The balance between model performance and interpretability is a key challenge in AI applications in healthcare, where complex models may be less likely to be adopted by clinicians despite their potential performance gains [25]. There is a need for future work to consider hybrid models that combine predictive accuracy with explainability to provide accurate and interpretable models for clinical applications.

The results of this study are also applicable to other areas of health care. Similar predictive modeling approaches to the one used in this study have been successfully used in other health domains, such as the prediction of infectious diseases and population health [15]. This implies that the approaches used in this study might be extended to other areas of medicine, thus increasing their value. Additionally, the use of predictive modeling techniques in other domains, such as cybersecurity and environmental management, demonstrates the adaptability and potential of these models [8], [22]. This insight from other domains can strengthen and improve the flexibility of predictive approaches in healthcare.

The influence of new technologies on predictive modeling also needs to be taken into account. Technologies like nanomedicine and drug delivery technologies can work synergistically with predictive models to allow for targeted drug delivery [1], [13]. Likewise, developments in mRNA-based vaccines and modulating the tumor microenvironment are likely to impact future predictive models by adding new factors and treatment approaches [14]. Combining these new technologies with predictive analytics is an area of future research.

In addition, the growing number of large-scale genomic data sets and advances in computing power are likely to propel further development of predictive models. With the availability of more data, predictive models can be trained on larger and more representative data sets, enhancing their predictive power and robustness. But this also requires the development of new algorithms and data management approaches to manage the increasing amount of data. Data sharing and collaboration will be key to these developments and ensuring responsible data use.

Overall, this research shows that predictive modeling with genomic data is a valuable and feasible approach to better select patients for targeted cancer immunotherapy. By combining machine learning algorithms with biologically meaningful features, precise and explainable predictions can be made, overcoming clinical and economic challenges in cancer. The results have some limitations and challenges, but they offer a solid basis for further studies and demonstrate the promise of predictive modeling in cancer treatment. Further research to improve data collection, model development, and integration with clinical practice will be crucial to fully harness the potential of this approach in precision medicine.

## VI. Conclusion

This research aimed to establish a predictive modeling approach to define patient responses to targeted cancer immunotherapy using genomic information. This work shows that combining several genomic biomarkers with sophisticated machine learning models enhances the accuracy and robustness of predictions of treatment outcomes. Specifically, machine learning models that use ensemble methods and deep learning, with random forests and neural networks displaying the best results, have the advantage over conventional statistical methods in capturing nonlinear patterns from high-dimensional biomedical data.

The findings also demonstrate that predicting patient responses to immunotherapy requires multiple biomarkers. Rather, a Panel of Tumor mutational burden, immune-related gene expression, and microsatellite instability offers a more holistic view of tumor characteristics. Such a multi-feature approach is in line with the growing trend towards personalized medicine, where therapies are selected based on an individual's unique molecular characteristics. The framework can more accurately predict responders and non-responders, potentially leading to optimised therapy and better patient outcomes without exposure to potentially ineffective therapies.

The findings of this study also have important economic implications. The high price tag associated with targeted cancer immunotherapies makes predictive modeling a feasible approach to improve health care resource allocation. By minimising the use of ineffective therapies, costs are reduced, as well as improving patient safety and quality. This multifaceted approach highlights the importance of predictive analytics in patient care.

However, there are some limitations to these efforts. Using publicly available data may limit the applicability of the results, while the nature of genomic data still presents challenges for developing and explaining models. Furthermore, concerns about data security, privacy, and ethical considerations must be taken into account when using genomic predictive models. Collaboration between researchers, clinicians, and policymakers will help overcome these issues.

Continued research needs to validate our framework on real-world clinical data sets and extend the framework to other populations. Incorporating other data, such as proteomic and clinical imaging data, could also improve model performance. Additionally, the development of transparent and secure models for sharing medical data and explainable artificial intelligence techniques is anticipated to significantly contribute to the integration of predictive models into clinical practice.

Overall, this study underscores the power of incorporating genomic data and machine learning to further pursue precision oncology. Predictive modeling is a valuable tool for optimizing treatment, cost-effectiveness, and ultimately the quality of care for cancer patients. Ongoing research in this area will be crucial in unlocking the potential of precision medicine.

## References

1. Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022, May 1). The Promise of Nanotechnology in Personalized Medicine. *Journal of Personalized Medicine*. MDPI. https://doi.org/10.3390/jpm12050673
2. Arbitrio, M., Milano, M., Lucibello, M., Altomare, E., Staropoli, N., Tassone, P., … Agapito, G. (2025). Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis. *Frontiers in Pharmacology*, *16*. https://doi.org/10.3389/fphar.2025.1548991
3. Cina, E., Elbasi, E., Elmazi, G., & AlArnaout, Z. (2025, June 1). The Role of AI in Predictive Modelling for Sustainable Urban Development: Challenges and Opportunities. *Sustainability (Switzerland)*. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/su17115148
4. Dobosz, P., & Dzieciątkowski, T. (2019, December 17). The Intriguing History of Cancer Immunotherapy. *Frontiers in Immunology*. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2019.02965
5. Elasan, S. (2023). Global Trends in Genomic Data Analyses: A Bibliometric Study. *Eastern Journal of Medicine*, *28*(4), 595–602. https://doi.org/10.5505/ejm.2023.53179
6. Field, M., Hardcastle, N., Jameson, M., Aherne, N., & Holloway, L. (2021, July 1). Machine learning applications in radiation oncology. *Physics and Imaging in Radiation Oncology*. Elsevier Ireland Ltd. https://doi.org/10.1016/j.phro.2021.05.007
7. Huang, H., Liu, R., Yang, J., Dai, J., Fan, S., Pi, J., … Guo, X. (2023, July 1). Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy. *Pharmaceutics*. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/pharmaceutics15071868
8. Kiran, U., Khan, N. F., Murtaza, H., Farooq, A., & Pirkkalainen, H. (2025). Explanatory and predictive modeling of cybersecurity behaviors using protection motivation theory. *Computers and Security*, *149*. https://doi.org/10.1016/j.cose.2024.104204

9. Kolisnik, T., Keshavarz-Rahaghi, F., Purcell, R. V., Smith, A. N. H., & Silander, O. K. (2025). pyRforest: a comprehensive R package for genomic data analysis featuring scikit-learn Random Forests in R. *Briefings in Functional Genomics*. Oxford University Press. https://doi.org/10.1093/bfgp/elae038
10. Kuo, T. T., Jiang, X., Tang, H., Wang, X. F., Harmanci, A., Kim, M., … Ohno-Machado, L. (2022, December 1). The evolving privacy and security concerns for genomic data analysis and sharing, as observed from the iDASH competition. *Journal of the American Medical Informatics Association*. Oxford University Press. https://doi.org/10.1093/jamia/ocac165
11. Lehmann, J., Cofala, T., Tschuggnall, M., Giesinger, J. M., Rumpold, G., & Holzner, B. (2021). Machine learning in oncology—Perspectives in patient-reported outcome research. *Der Onkologe*, *27*(S2), 150–155. https://doi.org/10.1007/s00761-021-00916-9
12. Li, W., Kim, M., Zhang, K., Chen, H., Jiang, X., & Harmanci, A. (2023). COLLAGENE enables privacy-aware federated and collaborative genomic data analysis. *Genome Biology*, *24*(1). https://doi.org/10.1186/s13059-023-03039-z
13. Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., … Han, P. (2024, December 1). Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. *Journal of Hematology and Oncology*. BioMed Central Ltd. https://doi.org/10.1186/s13045-024-01535-8
14. Miao, L., Zhang, Y., & Huang, L. (2021, December 1). mRNA vaccine for cancer immunotherapy. *Molecular Cancer*. BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01335-5
15. Ogwel, B., Mzazi, V., Nyawanda, B. O., Otieno, G., & Omore, R. (2024, January 1). Predictive modeling for infectious diarrheal disease in pediatric populations: A systematic review. *Learning Health Systems*. John Wiley and Sons Inc. https://doi.org/10.1002/lrh2.10382
16. Olawade, D. B., Kade, A., Egbon, E., Usman, S. O., Fapohunda, O., Ijiwade, J., & Ogbonna, C. E. (2025, December 1). Bioinformatics and artificial intelligence in genomic data analysis: current advances and future directions. *Molecular Genetics and Genomics*. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00438-025-02314-x
17. Rui, R., Zhou, L., & He, S. (2023). Cancer immunotherapies: advances and bottlenecks. *Frontiers in Immunology*. Frontiers Media SA. https://doi.org/10.3389/fimmu.2023.1212476
18. Singh, D., Dhiman, V. K., Pandey, M., Dhiman, V. K., Sharma, A., Pandey, H., … Pandey, R. (2024). Personalized medicine: An alternative for cancer treatment. *Cancer Treatment and Research Communications*, *42*. https://doi.org/10.1016/j.ctarc.2024.100860
19. Šket, K., Brezočnik, M., Karner, T., Belšak, R., Ficko, M., Vuherer, T., & Gotlih, J. (2025). Predictive Modelling of Weld Bead Geometry in Wire Arc Additive Manufacturing. *Journal of Manufacturing and Materials Processing*, *9*(2). https://doi.org/10.3390/jmmp9020067
20. Stefanicka-Wojtas, D., & Kurpas, D. (2023). Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). *Journal of Personalized Medicine*, *13*(3). https://doi.org/10.3390/jpm13030380
21. Toma, M., & Wei, O. C. (2023). Predictive Modeling in Medicine. *Encyclopedia*, *3*(2), 590–601. https://doi.org/10.3390/encyclopedia3020042
22. Ukoba, K., Onisuru, O. R., Jen, T. C., Madyira, D. M., & Olatunji, K. O. (2025, April 1). Predictive modeling of climate change impacts using Artificial Intelligence: a review for equitable governance and sustainable outcomes. *Environmental Science and Pollution Research*. Springer. https://doi.org/10.1007/s11356-025-36356-w
23. Vaz, V. M., & Kumar, L. (2021, January 1). 3D Printing as a Promising Tool in Personalized Medicine. *AAPS PharmSciTech*. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1208/s12249-020-01905-8
24. Wilson, S. B., Ward, J., Munjal, V., Lam, C. S. A., Patel, M., Zhang, P., … Chakravarthy, V. B. (2025, January 1). Machine Learning in Spine Oncology: A Narrative Review. *Global Spine Journal*. SAGE Publications Ltd. https://doi.org/10.1177/21925682241261342
25. Yang, C. C. (2022). Explainable Artificial Intelligence for Predictive Modeling in Healthcare. *Journal of Healthcare Informatics Research*, *6*(2), 228–239. https://doi.org/10.1007/s41666-022-00114-1